磷酸二叔丁酯乙酯 | 14540-31-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 中文名称: 磷酸二叔丁酯乙酯
• 英文名称: phosphoric acid di-tert-butyl ester ethyl ester
• 英文别名: Ethyl-di-tert-butyl-phosphat；Ditert-butyl ethyl phosphate
• CAS: 14540-31-9
• 化学式: C₁₀H₂₃O₄P
• 分子量: 238.264
• InChiKey: URWFYKDUIANHIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  磷酸二叔丁酯乙酯 、 三氟乙酸 生成 磷酸单乙基酯
  参考文献：
  名称：

  MLOTKOWSKA B.; ZWIERZAK A., POL. J. CHEM., 1979, 53, NO 1, 359-366

  摘要：

  DOI：
• 作为产物：
  描述：

  乙醇 、 双-叔丁基磷酸 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 苯 为溶剂， 生成 磷酸二叔丁酯乙酯
  参考文献：
  名称：

  Mlotkowska,B.; Zwierzak,A., Polish Journal of Chemistry, 1979, vol. 53, p. 359 - 366

  摘要：

  DOI：

文献信息

• [EN] PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DERIVES DE PHOSPHONOOXY QUINAZOLINE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2004058781A1

  公开（公告）日：2004-07-15

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  式(I)中的喹唑啉衍生物，其中A是含有一个氮原子和一个或两个进一步氮原子的5-成员杂环芳基；含有它们的组合物，其制备方法以及它们在治疗中的用途。
• [EN] METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS<br/>[FR] METHODES ET COMPOSITIONS A BASE DE NOUVEAUX COMPOSES DE TRIAZINE
  申请人：REDDY US THERAPEUTICS INC

  公开号：WO2004026844A1

  公开（公告）日：2004-04-01

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状况的化合物的方法和组合物。特别是，本发明涉及抑制或阻断在内皮细胞中由糖化蛋白产生的与信号传递相关的炎症反应的化合物。本发明还涉及抑制平滑肌细胞增殖的化合物。特别是，本发明涉及通过调节诸如Perlecan的HSPGs来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物来治疗由平滑肌增殖特征的心血管闭塞性状况，如再狭窄和动脉粥样硬化。
• 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS
  申请人：Kumar Sukeerthi

  公开号：US20120157411A1

  公开（公告）日：2012-06-21

  The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明涉及2-氨基-4-芳基噻唑衍生物作为TRPA（瞬时受体电位亚家族A）调节剂。具体来说，本文描述的化合物对于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、症状和/或疾病具有用处。本文还提供了制备所述化合物的方法，用于合成它们的中间体，它们的药物组成物，以及治疗或预防由TRPA1调节的疾病、症状和/或疾病的方法。
• Methods and compositions of novel triazine compounds
  申请人：——

  公开号：US20040209881A1

  公开（公告）日：2004-10-21

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及治疗由炎症反应引起的病理生理状况的方法和组合物，具体而言，本发明涉及抑制或阻断糖化蛋白诱导内皮细胞中与信号相关的炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物，具体而言，本发明涉及通过调节HSPGs（如Perlecan）来抑制平滑肌细胞增殖的化合物。本发明还涉及利用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化。
• Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity
  申请人：Liu Cuixan

  公开号：US20090304605A1

  公开（公告）日：2009-12-10

  The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II where A is a group of the formula: and the variables X, Y, R, and R 1 to R 7 are described herein. These compounds are prodrugs of compounds useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds are also provided by the invention.

  该发明提供了公式I和公式II的氨基取代氨噻唑化合物，其中A是以下式的基团：变量X、Y、R和R1至R7如本文所述。这些化合物是可用作抑制病毒复制的化合物的前药。该发明还提供了含有这些化合物的组合物，以及使用这些化合物治疗病毒感染的方法，以及用于制备这些化合物的过程和中间体。